

=> d que stat l61

L54 28 SEA FILE=REGISTRY ABB=ON 154357-42-3/CRN
 L55 1448 SEA FILE=REGISTRY ABB=ON 74-79-3/CRN
 L56 12 SEA FILE=REGISTRY ABB=ON L54 AND L55
 L61 9 SEA FILE=HCAPLUS ABB=ON L56 AND (PRD<20030925 OR PD<20030925)

=> d ibib abs hitstr l61 1-9

L61 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:220137 HCAPLUS

DOCUMENT NUMBER: 142:303550

TITLE: A process for the preparation of crystalline
 benzoquinolizine-2-carboxylic acid arginine salt
 tetrahydrate

INVENTOR(S): Deshpande, Prasad K.; Desai, Vijaya N.; Yeole,
 Ravindra D.; Gupte, Shrikant V.; Patel, Mahesh V.; De
 Souza, Noel J.

PATENT ASSIGNEE(S): Wockhardt Limited, India

SOURCE: U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005054666	A1	20050310	US 2003-749932	20031231 <--
WO 2005023805	A1	20050317	WO 2003-IN421	20031231 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2003-MU915 A 20030904 <--

AB The invention relates to a process for producing crystalline
 S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-
 1H,5H-benzo[i,j]quinolizine-2-carboxylic acid L-arginine salt (I)
 tetrahydrate, a process for its preparation and pharmaceutical formulations
 incorporating it as the active ingredient for use in treating microbial
 infections. The arginine salt of the acid was dissolved in a mixture of
 acetone and water and the solution obtained was evaporated slowly to give
 single
 crystals of I.

IT 847545-29-3

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP
 (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC
 (Process); USES (Uses)

(process for preparation of crystalline benzoquinolizinecarboxylic acid
 arginine
 salt tetrahydrate)

RN 847545-29-3 HCAPLUS

CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-
 methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], tetrahydrate (9CI)


(CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



IT 306748-89-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(process for preparation of crystalline benzoquinolizinecarboxylic acid
 arginine
 salt tetrahydrate)

RN 306748-89-0 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-
 methyl-1-oxo-1H,5H-benzo[5,6-j]quinolin-2-carboxylate] (9CI) (CA INDEX
 NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



L61 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:565121 HCAPLUS

DOCUMENT NUMBER: 141:111586

TITLE: Compositions of benzoquinolizinecarboxylic acid drugs and use for treatment or prevention of infective disease

INVENTOR(S): Saoji, Dilip G.; Nagori, Rajendra N.; Shetty, Nitin; Shukla, Milind C.; De, Souza, Noel J.

PATENT ASSIGNEE(S): India

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058303	A2	20040715	WO 2003-IN423	20031231 <--
WO 2004058303	A3	20040826		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2004176321 A1 20040909 US 2003-749931 20031231 <--
 PRIORITY APPLN. INFO.: IN 2002-MU1169 A 20021231 <--
 OTHER SOURCE(S): MARPAT 141:111586

AB The present invention relates to a pharmaceutical composition in aqueous solution form useful for parenteral application to a subject for treatment or prevention of an infective disease. In particular the present invention relates to such a composition having as an active agent, e.g.,

S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid or S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid arginine salt (I) or a benzoquinolizine-2-carboxylic acid. Thus, a solution contained I 0.9 and L-arginine 0.30 g, and water for injection qs to 100 mL.

IT 306748-89-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compsn. of benzoquinolizinecarboxylic acid drugs for treatment or prevention of infective disease)

RN 306748-89-0 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



L61 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:565095 HCAPLUS
 DOCUMENT NUMBER: 141:111581
 TITLE: Benzoquinolizine-2-carboxylic acid-containing compositions
 INVENTOR(S): Saoji, Dilip G.; Nagori, Rajendra N.; Shukla, Milind C.; Bhagwat, Sachin S.; Gupta, Shrikant V.; Patel, Mahesh V.; Jha, Rasendrakumar; Kukreja, Anil; De Souza, Noel J.
 PATENT ASSIGNEE(S): India
 SOURCE: PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058262	A1	20040715	WO 2003-IN422	20031231 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004176337	A1	20040909	US 2003-749933	20031231 <--
PRIORITY APPLN. INFO.:		IN 2002-MU1170	A 20021231 <--	
OTHER SOURCE(S): MARPAT 141:111581				

AB The invention relates to topical compns. of an antibacterial benzoquinolizine-2-carboxylic acid, incorporated either as the single therapeutic ingredient in hitherto undescribed pharmaceutical compns., or as an ingredient in novel combination with at least one agent selected from a retinoid, an antifungal agent, another antibacterial compound and/or a steroidal/nonsteroidal anti-inflammatory agent. Processes for preparation of the compns., the use of the compns. and a method of therapeutic or prophylactic use of such a composition for the treatment of dermal, ophthalmic, otic and nasal infections, with or without attendant inflammation are disclosed. Thus, a gel contained RS-(+)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid 1.00, Carbopol 1.20, NaOH 0.112, diethanolamine 0.36, disodium edetate 0.10, sodium sulfite 0.05, and water qs to 100%.

IT 306748-89-0


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (benzoquinolizinecarboxylic acid-containing topical compns.)

RN 306748-89-0 HCAPLUS
 CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3
 CMF C19 H21 F N2 O4


Absolute stereochemistry. Rotation (-).



CM 2

CRN 74-79-3
 CMF C6 H14 N4 O2

Absolute stereochemistry.



L61 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:485161 HCAPLUS

DOCUMENT NUMBER: 141:54197

TITLE: Preparation of optically pure benzoquinolizinecarboxylates as antibacterials.

INVENTOR(S): Patel, Mahesh Vithalbhai; Agarwal, Shivkumar; Kandepu, Sreenivas; Shetty, Nitin; Upadhyay, Dilip; Chaturvedi, Nishith; Thomas, Abraham; De Souza, Noel John; Khorakiwala, Habil Fakhruddin

PATENT ASSIGNEE(S): Wockhardt Limited, India

SOURCE: U.S., 36 pp., Cont.-in-part of U.S. Ser. No. 566,875. CODEN: USXXAM


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6750224	B1	20040615	US 2000-640947	20000817 <--
US 2003207908	A1	20031106	US 2000-566875	20000508 <--
CA 2403264	AA	20011115	CA 2001-2403264	20010503 <--
WO 2001085095	A2	20011115	WO 2001-IN97	20010503 <--
WO 2001085095	A3	20021003		
WO 2001085095	B1	20021227		
W: AE, AG, AT, AU, BG, BR, BZ, CA, CN, DE, DK, GH, HU, ID, IN, IS, KR, LS, LT, LV, MA, MN, PL, PT, RO, RU, TM, TT, TZ, UZ, YU, ZA, BY, MD, RU, TJ, TM				
RW: GH, GM, LS, MW, SD, SL, TZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, ES, TR, BF, CF, CI, MR, NE, SN, TD, TG				
AU 2001078666	A5	20011120	AU 2001-78666	20010503 <--
EP 1311506	A2	20030521	EP 2001-956751	20010503 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2417799	AA	20020207	CA 2001-2417799	20010731 <--
WO 2002009758	A2	20020207	WO 2001-IN139	20010731 <--
WO 2002009758	A3	20021227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001080091	A5	20020213	AU 2001-80091	20010731 <--
EP 1305048	A2	20030502	EP 2001-958373	20010731 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003144517	A1	20030731	US 2002-303692	20021122 <--
US 6753333	B2	20040622		
PRIORITY APPLN. INFO.:			US 1999-170676P	P 19991214 <--
			US 2000-566875	A2 20000508 <--
			WO 1999-IN16	A 19990507 <--
			US 2000-222201P	P 20000801 <--
			US 2000-640947	A 20000817 <--
			WO 2000-IN111	A 20001122 <--
			US 2001-802793	A 20010309 <--
			US 2001-286291P	P 20010425 <--
			WO 2001-IN97	W 20010503 <--
			US 2001-850669	A 20010507 <--
			WO 2001-IN100	A 20010508 <--
			WO 2001-IN139	W 20010731 <--
OTHER SOURCE(S):			MARPAT 141:54197	
GI				



AB Title compds. [I; X = OR₁, NHR₂; R₁ = H, pharmaceutically acceptable cation, alkyl, (CH₂)_nCHR₄O₂CR₅, acetoxymethyl, pivaloyloxymethyl, pivaloyloxyethyl, N-methylpiperidin-4-yl, pyrrolidin-2-ylethyl, piperidin-2-ylethyl, morpholin-2-ylethyl, etc.; R₂ = H, or NHR₂ = residue of a naturally occurring amino acid; R₃ = H, alkyl glycosyl, aralkyl, alkanoyl, aminoalkanoyl, gluconic acid, phosphoric acid, sulfuric acid derivs; R₄ = H, Me; R₅ = Et, CMe₃; and salts/hydrates thereof], were prepared. Thus, S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid in DMF at 50° was stirred 6 h with K₂CO₃ and chloromethyl pivalate was added followed by stirring for 40 h at 50° to give 71% pivaloyloxymethyl S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate. (S)-nadifloxacin showed a min. inhibitory concentration of 0.025 against Staphylococcus aureus ATCC 25923.

IT 306302-67-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of optically pure benzoquinolizinecarboxylates as antibacterials)

RN 306302-67-0 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate], hydrate (4:1) (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4


Absolute stereochemistry. Rotation (-).



CM 2

CRN 74-79-3
CMF C6 H14 N4 O2

Absolute stereochemistry.



REFERENCE COUNT: 114 THERE ARE 114 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:951022 HCAPLUS

DOCUMENT NUMBER: 140:8837

TITLE: Preparation of crystalline fluoroquinolone arginine salt form

INVENTOR(S): De Souza, Noel J.; Deshpande, Prasad K.; Shukla, Milind C.; Mukarram, Siddiqui M. Jaweed; Kulkarni, Dilip G.; Yeole, Ravindra D.; Patel, Mahesh V.; Gupte, Shrikant V.

PATENT ASSIGNEE(S): Wockhardt Limited, India

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099815	A1	20031204	WO 2002-IN123	20020528
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2459407	AA	20031204	CA 2002-2459407	20020528 <--
EP 1509519	A1	20050302	EP 2002-743615	20020528 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005527629	T2	20050915	JP 2004-507472	20020528 <--
PRIORITY APPLN. INFO.:			WO 2002-IN123	W 20020528 <--

AB The invention relates to the new arginine salt forms of RS-(±)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, R-(+)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-

methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their preparation and pharmaceutical formulations which comprise those arginine salt forms as the active ingredient for its use in treating microbial infections. Thus, S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid (I) was treated with L-arginine in acetone solution to give the I arginine salt.

IT 306748-89-0P 627891-29-6P 627891-34-3P

628705-85-1P 628705-87-3P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of crystalline fluoroquinolone arginine salts)

RN 306748-89-0 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 627891-29-6 HCAPLUS

CN L-Arginine, (5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate (3:2) (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3
CMF C19 H21 F N2 O4


Absolute stereochemistry. Rotation (-).



CM 2

CRN 74-79-3
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 627891-34-3 HCAPLUS
CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], monohydrate (9CI)
(CA INDEX NAME)

CM 1

CRN 154357-42-3
CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 628705-85±1 HCAPLUS


CN L-Arginine, (5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate, hydrate (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 628705-87-3 HCAPLUS

CN L-Arginine, (5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-


1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:950059 HCAPLUS

DOCUMENT NUMBER: 140:8806

TITLE: Preparation of crystalline fluoroquinolone arginine salts for pharmaceuticals

INVENTOR(S): De Souza, Noel J.; Deshpande, Prasad K.; Shukla, Milind C.; Jaweed, Mukarram Siddiqui M.; Kulkarni, Dilip Ganesh; Rahman, Ansari Azizur; Yeole, Ravindra D.; Patel, Mahesh V.; Gupta, Shrikant V.

PATENT ASSIGNEE(S): Wockhardt Limited, India

SOURCE: U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Searched by Mary Jane Ruhl Ext. 22524

Page 13

US 2003225119	A1	20031204	US 2002-156685	20020528
US 6664267	B2	20031216		
US 2004063948	A1	20040401	US 2003-671040	20030925 <--
PRIORITY APPLN. INFO.:			US 2002-156685	A3 20020528 <--

AB The invention relates to the new arginine salt forms of RS-(±)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid (I), R-(+)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their preparation and pharmaceutical formulations which comprise those arginine salt forms as the active ingredient for its use in treating microbial infections. I was suspended in acetone, and this suspension was mixed with L-arginine and water. The mixture was stirred at 55-60° to obtain a clear solution and to this solution was added activated carbon and the solution was filtered. To the filtrate was added acetone, and the reaction mixture was stirred for an addnl. for 2 h at 30-35°, and then allowed to cool to 5°. The obtained solid was filtered and washed with acetone. The wet solid was dried at 80-85° to afford the L L-arginine salt hydrate. as a cream colored powder.

IT 306302-67-0P 306302-69-2P 306748-89-0P
 371246-52-5P 627891-29-6P 627891-31-0P
 627891-34-3P 627891-36-5P 627891-38-7P
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of crystalline fluoroquinolone arginine salts for
 pharmaceuticals)

RN 306302-67-0 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:1)
 (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 306302-69-2 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:3) (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 306748-89-0 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 371246-52-5 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 627891-29-6 HCAPLUS


CN L-Arginine, (5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate (3:2) (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 627891-31-0 HCAPLUS

CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (2:1)


(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 627891-34-3 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], monohydrate (9CI)
(CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 627891-36-5 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], dihydrate (9CI)
(CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 627891-38-7 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], trihydrate (9CI)
(CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



L61 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:107157 HCAPLUS

DOCUMENT NUMBER: 136:167388

TITLE: Preparation and use of quinolone and naphthyridine derivatives as inhibitors of cellular efflux pumps of

INVENTOR(S) : microbes
De Souza, Noel J.; Patel, Mahesh V.; Gupta, Shrikant
V.; Upadhyay, Dilip J.; Shukla, Milind C.; Chaturvedi,
Nishith C.; Bhawsar, Satish B.; Nair, Sheela C.;
Jafri, Mohammed A.; Khorakiwala, Habil F.

PATENT ASSIGNEE(S) : Wockhardt Limited, India

SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002009758	A2	20020207	WO 2001-IN139	20010731 <--
WO 2002009758	A3	20021227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6750224	B1	20040615	US 2000-640947	20000817 <--
US 2002165227	A1	20021107	US 2001-850669	20010507 <--
US 6608078	B2	20030819		
CA 2417799	AA	20020207	CA 2001-2417799	20010731 <--
AU 2001080091	A5	20020213	AU 2001-80091	20010731 <--
US 2002177559	A1	20021128	US 2001-919347	20010731 <--
EP 1305048	A2	20030502	EP 2001-958373	20010731 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2000-222201P	P 20000801 <--
			US 2000-640947	A 20000817 <--
			WO 2000-IN111	W 20001122 <--
			US 2001-286291P	P 20010425 <--
			US 2001-850669	A 20010507 <--
			WO 2001-IN100	A 20010508 <--
			US 1999-170676P	P 19991214 <--
			US 2000-202459P	P 20000508 <--
			US 2000-566875	A2 20000508 <--
			WO 2001-IN139	W 20010731 <--
OTHER SOURCE(S) : GI			MARPAT 136:167388	



AB Title compds. I [R1 = H, (cyclo)alkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylSOO-2 alkyl or when X = C and the nitrogen atom to which R1 is linked forms an (un)substituted 4-7 membered ring with X of the adjacent ring, the ring optionally containing one or more hetero atoms selected from N, O, S, said heteroatom(s) represented by Y; R2 = H, CHO, COOR3, CONHR13, where R13 = H or the NHR13 of CONHR13 is the residue of an amino acid; R3 = H, alkyl, cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylSOO-2 alkyl, O-carboxy, etc.; R4 = H; R4' = H or R4 and R4' taken together are :O, :S; R5 = H, alkyl, amino, alkylamino, acylamino; R6 = H, alkyl, halo, amino, hydroxy; R7 = OH, halo, NR9R10, etc.; R9-10 = H, alkyl, (CH2)nOA or R9 = H and R10 = 4-7 membered carbocyclic, heterocyclic ring linked to the nitrogen of NR9R10 through an atom of the heterocycle other than the heterocyclic atom, etc.; A = H, alkyl, glycosyl, aralkyl, alkanoyl, aminoalkanoyl wherein the aminoalkanoyl group may be an amino acid residue or A is C6H11O6, SO3H, PO3H2; X = CH, CF, CCl, CCH3, CCF3, COCH3, COCHF2, C-OCF3, N or when X is equal to C it forms together with the nitrogen atom of the adjacent ring an (un)substituted 5-7 membered ring containing carbon atoms and optionally Y atoms representing one or more N, O, S] were prepared For instance, a mixture of 1-ethyl-6,7-difluoro-1,4-dihydro-4-oxoquinolone-3-carboxylic acid and 1,2,3,4-tetrahydroisoquinoline (DMSO, Et3N 140°C, 24 h) provided, after work-up and trituration II as a solid (62% yield), m.p. 220°C. II with ciprofloxacin had a fractional inhibitory concentration (FIC) index of 0.314 observed against *S. aureus* 1199 B (Nor A+). I are effective at inhibiting efflux pumps, e.g., MefA, MefE, Bmr, PmrA, etc.

IT **306748-89-0P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; preparation and use of quinolone and naphthyridine derivs. as inhibitors of cellular efflux pumps of microbes)

RN 306748-89-0 HCAPLUS

CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate] (9CI) (CA INDEX


NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



L61 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:833024 HCAPLUS

DOCUMENT NUMBER: 135:344388

TITLE: Preparation of chiral fluoroquinone arginine salt forms

INVENTOR(S): De Souza, Noel John; Agarwal, Shiv Kumar; Patel, Mahesh Vitalbhai; Bhawar, Satish Baliram; Beri, Rupinder Kaur; Yeole, Ravindra Dattatraya; Shetty, Nitin; Khorak Iwala, Habil Fakhud Din

PATENT ASSIGNEE(S): India

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085095	A2	20011115	WO 2001-IN97	20010503 <--

WO 2001085095 A3 20021003
 WO 2001085095 B1 20021227
 W: AE, AG, AT, AU, BG, BR, BZ, CA, CN, DE, DK, GH, HU, ID, IN, IS,
 KR, LS, LT, LV, MA, MN, PL, PT, RO, RU, TM, TT, TZ, UZ, YU, ZA,
 BY, MD, RU, TJ, TM
 RW: GH, GM, LS, MW, SD, SL, TZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
 FR, GB, GR, IE, IT, LU, MC, NL, ES, TR, BF, CF, CI, MR, NE, SN,
 TD, TG
 US 2003207908 A1 20031106 US 2000-566875 20000508 <--
 US 6750224 B1 20040615 US 2000-640947 20000817 <--
 US 2002061908 A1 20020523 US 2001-802793 20010309 <--
 US 6514986 B2 20030204
 CA 2403264 AA 20011115 CA 2001-2403264 20010503 <--
 AU 2001078666 A5 20011120 AU 2001-78666 20010503 <--
 EP 1311506 A2 20030521 EP 2001-956751 20010503 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:
 US 2000-566875 A 20000508 <--
 US 2000-640947 A 20000817 <--
 WO 2000-IN111 W 20001122 <--
 US 2001-802793 A 20010309 <--
 WO 1999-IN16 A 19990507 <--
 US 1999-170676P P 19991214 <--
 WO 2001-IN97 W 20010503 <--

AB The invention relates to new arginine salt forms of S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their preparation and pharmaceutical formulations which comprise those arginine salt forms as the active ingredient for use in treating antimicrobial infections. The salt was studied by X-ray diffraction anal. and differential scanning calorimetry.

IT 306748-89-0P 371246-52-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation, crystal structure, and thermal anal. of fluorodihydro(hydroxypiperidinyl)methyloxobenzoquinolizinecarboxylic acid arginine salt)

RN 306748-89-0 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 371246-52-5 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



L61 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:814485 HCAPLUS

DOCUMENT NUMBER: 133:350154

TITLE: Antibacterial optically pure
benzoquinolizinecarboxylic acid derivatives:
processes, compositions and methods of treatmentINVENTOR(S): Patel, M. V.; Gupte, S. V.; Chugh, Y.; Saoji, D. G.;
Agarwal, S. K.; De Souza, N. J.; Khorakiwala, H. F.

PATENT ASSIGNEE(S): India

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000068229	A2	20001116	WO 2000-IN54	20000508 <--
WO 2000068229	A3	20010322		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2373291	AA	20001116	CA 2000-2373291	20000508 <--
AU 2000054256	A5	20001121	AU 2000-54256	20000508 <--
EP 1175217	A2	20020130	EP 2000-939047	20000508 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2001085728	A2	20011115	WO 2001-IN100	20010508 <--
WO 2001085728	A3	20020912		
W: AL, AM, AU, AZ, BB, BG, CA, CH, CU, CZ, DE, DK, EE, ES, FI, GB, HR, HU, ID, IL, IN, KE, KP, TM, TZ, UA, VN, YU, ZA, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, DK, FI, FR, GB, GR, IT, LU, BJ, CG, GA, MR, SN, TD, TG				
PRIORITY APPLN. INFO.:		WO 1999-IN16 A 19990507 <--		
		US 1999-170676P P 19991214 <--		
		US 2000-566875 A 20000508 <--		
		WO 2000-IN54 W 20000508 <--		

OTHER SOURCE(S): CASREACT 133:350154; MARPAT 133:350154

GI



AB Title compds. (S)-(-)-I [X = OH, ONH₄, O-(substituted ammonium), NHR₁ (R₁ = H, amino acid residue), etc.; R = H, alkyl, glycosyl, aralkyl, etc.; HA is an acid; y = 0-3 or fractional number therein; z = 0, integer or fractional number], substantially free of their R-(+)-isomers, are prepared as antibacterial agents. Thus, 5.0 g (S)-(-)-I (R = H, X = OH, y = z = 0) was dissolved in 500 mL MeCN at 100° and filtered to remove suspended fibrous impurities, 1500 mL distilled water was added, and the mixture was allowed to stand overnight at 5° to give 3.5 g (70%) (S)-(-)-I (R = H, X = OH, y = 0, z = 0.2). Antibacterial tests were conducted against several microorganisms.

IT **306748-89-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306748-89-0 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



IT 306302-69-2P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306302-69-2 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:3)
(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



IT 306302-67-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306302-67-0 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



=> d que stat 160


L54 28 SEA FILE=REGISTRY ABB=ON 154357-42-3/CRN
 L55 1448 SEA FILE=REGISTRY ABB=ON 74-79-3/CRN
 L56 12 SEA FILE=REGISTRY ABB=ON L54 AND L55
 L58 1 SEA FILE=CASREACT ABB=ON L56
 L59 1 SEA FILE=CASREACT ABB=ON L56
 L60 1 SEA FILE=CASREACT ABB=ON L58 OR L59

=> d all 160 1-1

L60 ANSWER 1 OF 1 CASREACT COPYRIGHT 2005 ACS on STN
 AN 133:350154 CASREACT
 TI Antibacterial optically pure benzoquinolizinecarboxylic acid derivatives:
 processes, compositions and methods of treatment
 IN Patel, M. V.; Gupte, S. V.; Chugh, Y.; Saoji, D. G.; Agarwal, S. K.; De
 Souza, N. J.; Khorakiwala, H. F.
 PA India
 SO PCT Int. Appl., 85 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC C07D455-00
 CC 27-18 (Heterocyclic Compounds (One Hetero Atom))
 Section cross-reference(s): 1, 63

FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000068229	A2	20001116	WO 2000-IN54	20000508
	WO 2000068229	A3	20010322		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2373291	AA	20001116	CA 2000-2373291	20000508
	AU 2000054256	A5	20001121	AU 2000-54256	20000508
	EP 1175217	A2	20020130	EP 2000-939047	20000508
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	WO 2001085728	A2	20011115	WO 2001-IN100	20010508
	WO 2001085728	A3	20020912		
	W:	AL, AM, AU, AZ, BB, BG, CA, CH, CU, CZ, DE, DK, EE, ES, FI, GB, HR, HU, ID, IL, IN, KE, KP, TM, TZ, UA, VN, YU, ZA, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, DK, FI, FR, GB, GR, IT, LU, BJ, CG, GA, MR, SN, TD, TG			
PRAI	WO 1999-IN16		19990507		
	US 1999-170676P		19991214		
	US 2000-566875		20000508		
	WO 2000-IN54		20000508		
OS	MARPAT 133:350154				
GI					




- AB Title compds. (S)-(-)-I [X = OH, ONH₄, O-(substituted ammonium), NHR₁ (R₁ = H, amino acid residue), etc.; R = H, alkyl, glycosyl, aralkyl, etc.; HA is an acid; y = 0-3 or fractional number therein; z = 0, integer or fractional number], substantially free of their R-(+)-isomers, are prepared as antibacterial agents. Thus, 5.0 g (S)-(-)-I (R = H, X = OH, y = z = 0) was dissolved in 500 mL MeCN at 100° and filtered to remove suspended fibrous impurities, 1500 mL distilled water was added, and the mixture was allowed to stand overnight at 5° to give 3.5 g (70%) (S)-(-)-I (R = H, X = OH, y = 0, z = 0.2). Antibacterial tests were conducted against several microorganisms.
- ST benzoquinolizinecarboxylic acid deriv prepn antibacterial activity
- IT Antibacterial agents
(optically pure benzoquinolizinecarboxylic acid derivs.)
- IT 154357-42-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)
- IT 306748-89-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)
- IT 306302-57-8P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)
- IT 306302-63-6P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)
- IT 572-09-8, Acetobromoglucose 625-56-9, Chloromethyl acetate 927-68-4, 2-Bromoethyl acetate 2483-46-7, 4045-24-3, 4-Methoxypiperidine 5292-43-3, tert-Butyl bromoacetate 18997-19-8, Chloromethyl pivalate 51479-37-9, 2-Chloroethyl pivalate 154357-41-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)
- IT 306302-59-0P 306302-69-2P 306302-92-1P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)
- IT 306302-61-4P 306302-65-8P 306302-67-0P 306302-71-6P 306302-74-9P
306302-76-1P 306302-78-3P 306302-80-7P 306302-82-9P 306302-84-1P
306302-86-3P 306302-88-5P 306302-90-9P 306302-94-3P 306302-96-5P


306302-98-7P 306303-00-4P 306303-02-6P 306303-04-8P 306303-06-0P
306303-08-2P 306303-11-7P 306303-13-9P 306303-15-1P 306303-17-3P
306303-19-5P 306303-21-9P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RX(1) OF 20 A ==> B



A



● 1/5 H₂O

B

YIELD 70%

RX(1) RCT A 154357-42-3

STAGE(1)

SOL 75-05-8 MeCN


STAGE(2)

SOL 7732-18-5 Water


PRO B 306302-57-8

NTE STEREOSELECTIVE

RX(2) OF 20 A ==> E



A

(2) \rightarrow ● 1/2 H₂OE
YIELD 78%

RX(2) RCT A 154357-42-3

STAGE(1)

SOL 67-64-1 Me₂CO


STAGE(2)

SOL 7732-18-5 Water

PRO E 306302-59-0


NTE STEREOSELECTIVE

RX(3) OF 20 A ==> G



A


(3) →

● 3/4 H₂OG
YIELD 30%

RX(3) RCT A 154357-42-3

STAGE(1)
SOL 7732-18-5 WaterSTAGE(2)
SOL 67-64-1 Me₂COPRO G 306302-61-4
NTE STEREOSELECTIVE

RX(4) OF 20 A ==> H




A




* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

RX(4) RCT A 154357-42-3
 RGT I 1310-73-2 NaOH
 PRO H 306302-63-6
 SOL 75-05-8 MeCN
 NTE STEREOSELECTIVE


RX(5) OF 20 J + A ==> K




J



A




K: CM 1
 YIELD 93%




K: CM 2
YIELD 93%

RX(5) RCT J 74-79-3, A 154357-42-3
PRO K **306302-67-0**
SOL 67-56-1 MeOH
NTE STEREOSELECTIVE

RX(6) OF 20 A + M ==> N




A




M

(6) →




N: CM 1
YIELD 99%



N: CM 2
YIELD 99%

RX(6) RCT A 154357-42-3, M 56-87-1
PRO N 306302-71-6
SOL 67-56-1 MeOH
NTE STEREOSELECTIVE


RX(7) OF 20 A + O ==> P




A

O

(7) >





P: CM 1
YIELD 94%



P: CM 2
YIELD 94%

RX(7) RCT A 154357-42-3, O 71-00-1
 PRO P 306302-74-9
 SOL 67-56-1 MeOH
 NTE STEREOSELECTIVE

RX(8) OF 20 A + Q ==> R



R
 YIELD 95%

RX(8) RCT A 154357-42-3, Q 108-24-7

STAGE(1)



RGT S 1122-58-3 4-DMAP
 SOL 110-86-1 Pyridine

STAGE(2)

SOL 7732-18-5 Water

PRO R 306302-88-5
 NTE STEREOSELECTIVE

RX(9) OF 20 A + U ==> V



YIELD 50%

RX(9) RCT A 154357-42-3, U 3282-30-2

STAGE(1)

RGT S 1122-58-3 4-DMAP

SOL 110-86-1 Pyridine


STAGE(2)

SOL 7732-18-5 Water

PRO V 306302-90-9


NTE STEREOSELECTIVE

RX(10) OF 20 ...W ==> X



W

(10) →



X

RX(10) RCT W 306302-92-1

STAGE(1)

RGT Y 1310-65-2 LiOH

SOL 67-56-1 MeOH, 7732-18-5 Water


STAGE(2)

SOL 67-56-1 MeOH


PRO X 306302-94-3

NTE STEREOSELECTIVE

RX(11) OF 20 A + Z ==> AA




A



Z

(11) →



AA
YIELD 30%

RX(11) RCT A 154357-42-3

STAGE(1)

RGT AB 121-44-8 Et3N, AC 543-27-1 ClCO2Bu-i
SOL 127-19-5 AcNMe2

STAGE(2)

RCT Z 6525-53-7

STAGE(3)

RGT AD 7647-01-0 HCl
SOL 141-78-6 AcOEt

STAGE(4)

RGT I 1310-73-2 NaOH
SOL 67-56-1 MeOH

STAGE(5)

RGT AD 7647-01-0 HCl



STAGE(6)

SOL 141-78-6 AcOEt

PRO AA 306302-96-5

NTE STEREOSELECTIVE

RX(12) OF 20 A + AG ==> AH



YIELD 71%

RX(12) RCT A 154357-42-3, AG 18997-19-8

STAGE(1)

RGT AI 584-08-7 K₂CO₃

SOL 68-12-2 DMF



STAGE(2)

SOL 7732-18-5 Water

PRO AH 306302-76-1

NTE STEREOSELECTIVE

RX(13) OF 20 A + AK ==> AL



AL
YIELD 56%

RX(13) RCT A 154357-42-3, AK 625-56-9

STAGE(1)

RGT AI 584-08-7 K₂CO₃

SOL 68-12-2 DMF


STAGE(2)

SOL 7732-18-5 Water


PRO AL 306302-78-3

NTE STEREOSELECTIVE


RX(14) OF 20 A + AM ==> AN



A



AM

(14)
→AN
YIELD 59%

RX(14) RCT A 154357-42-3, AM 51479-37-9

STAGE(1)

RGT AI 584-08-7 K₂CO₃

SOL 68-12-2 DMF



STAGE(2)

SOL 7732-18-5 Water

PRO AN 306302-80-7

NTE STEREOSELECTIVE

RX(15) OF 20 A + AO ==> AP



AP
YIELD 67%

RX(15) RCT A 154357-42-3, AO 77442-80-9

STAGE(1)

RGT AI 584-08-7 K₂CO₃

SOL 68-12-2 DMF



STAGE(2)

SOL 7732-18-5 Water

PRO AP 306302-82-9

NTE STEREOSELECTIVE

RX(16) OF 20 A + AQ ==> AR



AR
YIELD 80%

RX(16) RCT A 154357-42-3, AQ 5292-43-3

STAGE(1)

RGT AI 584-08-7 K₂CO₃

SOL 68-12-2 DMF



STAGE(2)

SOL 7732-18-5 Water

PRO AR 306302-84-1

NTE STEREOSELECTIVE

RX(17) OF 20 AS + AT ==> AU



YIELD 38%

RX(17) RCT AS 154357-41-2, AT 4045-24-3

STAGE(1)

SOL 75-05-8 MeCN

STAGE(2)

SOL 7732-18-5 Water

STAGE(3)

RGT I 1310-73-2 NaOH

SOL 75-05-8 MeCN


STAGE(4)

RGT AD 7647-01-0 HCl


PRO AU 306302-86-3

NTE STEREOSELECTIVE

RX(18) OF 20 AV + A ==> W...




AV



A


(18) \rightarrow




W

RX'(18) RCT AV 572-09-8, A 154357-42-3
 RGT AW 534-16-7 Ag₂CO₃
 PRO W 306302-92-1
 NTE STEREOSELECTIVE, MOLECULAR SIEVES USED


RX(19) OF 20 AX + A ==> AY



AX



A



● 2 HCl

AY
YIELD 69%

RX(19) RCT AX 2483-46-7, A 154357-42-3

STAGE(1)

RGT AB 121-44-8 Et₃N, S 1122-58-3 4-DMAP
SOL 127-19-5 AcNMe₂

STAGE(2)

RGT AZ 538-75-0 DCC

STAGE(3)

SOL 141-78-6 AcOEt

STAGE(4)

RGT BA 76-05-1 F3CCO2H

STAGE(5)

SOL 60-29-7 Et2O

PRO AY 306302-98-7

NTE STEREOSELECTIVE

=> d que stat 162

L54 28 SEA FILE=REGISTRY ABB=ON 154357-42-3/CRN
 L55 1448 SEA FILE=REGISTRY ABB=ON 74-79-3/CRN
 L56 12 SEA FILE=REGISTRY ABB=ON L54 AND L55
 L62 11 SEA FILE=USPATFULL ABB=ON L56 AND (PRD<20030925 OR PD<20030925
)

=> => d ibib abs hitstr 162 1-11

L62 ANSWER 1 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2005:75863 USPATFULL

TITLE: Generation triple-targeting, chiral, broad-spectrum
 antimicrobial 7-substituted piperidino-quinolone
 carboxylic acid derivatives, their preparation,
 compositions and use as medicaments

INVENTOR(S): De Souza, Noel John, Mumbai, INDIA
 Patel, Mahesh Vithalbhair, Aurangabad, INDIA
 Deshpande, Prasad Keshav, Aurangabad, INDIA
 Agarwal, Shiv Kumar, Aurangabad, INDIA
 Sreenivas, Kandepu, Aurangabad, INDIA
 Nair, Sheela Chandrasekharan, Aurangabad, INDIA
 Chugh, Yati, Aurangabad, INDIA
 Shukla, Milind Chintaman, Aurangabad, INDIA

PATENT ASSIGNEE(S): WOCKHARDT LIMITED (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005065164	A1	20050324
APPLICATION INFO.:	US 2004-945504	A1	20040920 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-318367, filed on 12 Dec 2002, PENDING Continuation-in-part of Ser. No. US 2002-128996, filed on 23 Apr 2002, PENDING		

	NUMBER	DATE	
PRIORITY INFORMATION:	WO 2002-IN111	20020424	<--
	US 2001-286291P	20010425 (60)	<--
	US 2001-341165P	20011213 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LADAS & PARRY, 26 WEST 61ST STREET, NEW YORK, NY, 10023		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	CLM-001-5		
LINE COUNT:	6390		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to new generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, to their optical isomers, diastereomers or enantiomers, as well as pharmaceutically acceptable salts, hydrates, prodrugs, polymorphs and pseudopolymorphs thereof, to their preparation, to their compositions and to their use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 306748-89-0P

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306748-89-0 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



IT 306302-69-2P

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306302-69-2 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:3)
(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



IT 306302-67-0P

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306302-67-0 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



L62 ANSWER 2 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2005:63624 USPATFULL

TITLE: Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate

INVENTOR(S): Deshpande, Prasad K., Aurangabad, INDIA
 Desai, Vijaya N., Aurangabad, INDIA
 Yeole, Ravindra D., Aurangabad, INDIA
 Gupte, Shrikant V., Aurangabad, INDIA
 Patel, Mahesh V., Aurangabad, INDIA
 de Souza, Noel J., Mumbai, INDIA

PATENT ASSIGNEE(S): WOCKHARDT LIMITED (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005054666	A1	20050310
APPLICATION INFO.:	US 2003-749932	A1	20031231 (10)

not good date

	NUMBER	DATE
PRIORITY INFORMATION:	IN 2003-9152003	20030904
DOCUMENT TYPE:	Utility	<--
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Ladas & Parry, 26 West 61 Street, New York, NY, 10023	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	676	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to crystalline S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid L-arginine salt tetrahydrate, a process for its preparation and pharmaceutical formulations incorporating it as the active ingredient for use in treating microbial infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 847545-29-3

(process for preparation of crystalline benzoquinolizinecarboxylic acid arginine salt tetrahydrate)

RN 847545-29-3 USPATFULL

CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], tetrahydrate


(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



IT 306748-89-0

(process for preparation of crystalline benzoquinolizinecarboxylic acid arginine

salt tetrahydrate)

RN 306748-89-0 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



L62 ANSWER 3 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2004:227951 USPATFULL

TITLE: Benzoquinolizine-2-carboxylic acid-containing compositions

INVENTOR(S): Saoji, Dilip G., Aurangabad, INDIA
 Nagori, Rajendra N., Aurangabad, INDIA
 Shukla, Milind C., Aurangabad, INDIA
 Bhagwat, Sachin, Aurangabad, INDIA
 Gupte, Shrikant V., Aurangabad, INDIA
 Patel, Mahesh V., Aurangabad, INDIA
 Jha, Rasendrakumar, Mumbai, INDIA
 Kukreja, Anil, Mumbai, INDIA
 De Souza, Noel J., Mumbai, INDIA

PATENT ASSIGNEE(S): WOCKHARDT LIMITED (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004176337	A1	20040909
APPLICATION INFO.:	US 2003-749933	A1	20031231 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	IN 2002-11702002	20021231
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Ladas & Parry, 26 West 61 Street, New York, NY, 10023	
NUMBER OF CLAIMS:	37	

EXEMPLARY CLAIM: 1

LINE COUNT: 1060

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to topical compositions of an antibacterial benzoquinolizine-2-carboxylic acid, incorporated either as the single therapeutic ingredient in hitherto undescribed pharmaceutical compositions, or as an ingredient in novel combination with at least one agent selected from a retinoid, an antifungal agent, another antibacterial compound and/or a steroid/non-steroid anti-inflammatory agent, to processes for preparation of the compositions, to use of the compositions in preparation of a medicament, and to a method of therapeutic or prophylactic use of such a composition for the treatment of dermal, ophthalmic, otic and nasal infections, with or without attendant inflammation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 306748-89-0

(benzoquinolizinecarboxylic acid-containing topical compns.)

RN 306748-89-0 USPTFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



L62 ANSWER 4 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2004:227935 USPATFULL
TITLE: Compositions of benzoquinolizine carboxylic acid
antibiotic drugs
INVENTOR(S): Saoji, Dilip G., Aurangabad, INDIA
Nagori, Rajendra N., Aurangabad, INDIA
Yeole, Ravindra D., Aurangabad, INDIA
Shetty, Nitin, Aurangabad, INDIA
Shukla, Milind C., Aurangabad, INDIA
de Souza, Noel J., Mumbai, INDIA
PATENT ASSIGNEE(S): WOCKHARDT LIMITED (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004176321	A1	20040909
APPLICATION INFO.:	US 2003-749931	A1	20031231 (10)

no good det

	NUMBER	DATE
PRIORITY INFORMATION:	IN 2002-11692002	20021231
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Ladas & Parry, 26 West 61 Street, New York, NY, 10023	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1440	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a pharmaceutical composition in aqueous solution form useful for parenteral application to a subject for treatment or prevention of infective disease. In particular the present invention relates to such a composition having as an active agent S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid 0.2 hydrate or S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid arginine salt or a benzoquinolizine-2-carboxylic acid antibiotic drug. The field of the invention also includes processes for the preparation of such a composition, the use of such a composition in preparation of a medicament, and to the therapeutic or prophylactic use of such a composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 306748-89-0

(comps. of benzoquinolizinecarboxylic acid drugs for treatment or prevention of infective disease)

RN 306748-89-0 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



L62 ANSWER 5 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2004:146965 USPATFULL

TITLE: Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment

INVENTOR(S): Patel, Mahesh Vithalbhai, Aurangabad, INDIA

Agarwal, Shivkumar, Aurangabad, INDIA

Kandepu, Sreenivas, Guntar, INDIA

Shetty, Nitin, Kalyan, INDIA

Upadhyay, Dilip, Kalyan, INDIA

Chaturvedi, Nishith, Aurangabad, INDIA

Thomas, Abraham, Aurangabad, INDIA

De Souza, Noel John, Mumbai, INDIA

Khorakiwala, Habil Fakhruddin, Mumbai, INDIA

PATENT ASSIGNEE(S): Wockhardt Limited, Bandra (East) Mumbai, INDIA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6750224	B1	20040615
APPLICATION INFO.:	US 2000-640947		20000817 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-566875, filed on 8 May 2000		

no good date

NUMBER	DATE

PRIORITY INFORMATION: US 1999-170676P 19991214 (60) <--
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Rotman, Alan L.
ASSISTANT EXAMINER: Truong, Tamthom N.
LEGAL REPRESENTATIVE: Ladas & Parry
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 2607
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to optically pure S-(-)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof, substantially free of their R-(+)-isomers, to processes for preparation of the optically pure S-(-)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof substantially free of their R-(+)-isomers, and to pharmaceutical compositions comprising the S(-)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof. These compounds and compositions can be used to systemically and topically treat bacterial Gram-positive, Gram-negative and anaerobic infections, specially resistant Gram-positive organism infections, Gram-negative organism infections, mycobacterial infections and emerging nosocomial pathogen infections, while avoiding toxic effects associated with the administration of the racemic mixture of RS-(±)-benzoquinolizine carboxylic acid. The compounds and compositions of this invention can also be used to treat diseases and disorders caused by Gram-positive, Gram-negative and anaerobic bacteria, and diseases and disorders caused by resistant Gram-positive organisms, Gram-negative organisms, mycobacteria and nosocomial pathogens.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 306302-67-0P

(preparation of optically pure benzoquinolizinecarboxylates as antibacterials)

RN 306302-67-0 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:1) (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



L62 ANSWER 6 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2003:294890 USPATFULL

TITLE: Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment

INVENTOR(S): Patel, Mahesh Vithalbhai, Aurangabad, INDIA
 Agarwal, Shivkumar, Aurangabad, INDIA
 Kandepu, Sreenivas, Guntur-Dist., INDIA
 Shetty, Nitin, Kalyan, INDIA
 Upadhyay, Dilip Jatashankar, Kalyan, INDIA
 Chaturvedi, Nishith Chandra, Aurangabad, INDIA
 Thomas, Abraham, Aurangabad, INDIA
 De Souza, Noel John, Mumbai, INDIA
 Khorakiwala, Habil Fakhruddin, Mumbai, INDIA

not good date

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207908	A1	20031106
APPLICATION INFO.:	US 2000-566875	A1	20000508 (9)

	NUMBER	DATE	
PRIORITY INFORMATION:	WO 1999-IN16	19990507	<--
	US 1999-170676P	19991214 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LADAS & PARRY, 26 WEST 61ST STREET, NEW YORK, NY, 10023		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Page(s)		
LINE COUNT:	2484		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to optically pure S-(-)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof, substantially free of their R-(+)-isomers, to processes for preparation of the optically pure S-(-)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof substantially free of their R-(+)-isomers, and to pharmaceutical compositions comprising the S-(+)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs

and hydrates thereof. These compounds and compositions can be used to systemically and topically treat bacterial Gram-positive, Gram-negative and anaerobic infections, specially resistant Gram-positive organism infections, Gram-negative organm infections, mycobacterial infections and emerging nosocomlal pathogen infections, while avoiding toxic effects associated with the administration of the racemic mixture of RS-(±)-benzoquinolizine carboxylic acid. The compounds and compositions of this invention can also be need to treat diseases and disorders caused by Gram-positive, Gram-negative and anaerobic bacteria, and diseases and disorders caused by resistant Gram-positive organisms, Gram-negative organisms, mycobacteria and nosocomial pathogens.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **306748-89-0P**

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306748-89-0 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-) ..




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



IT **306302-69-2P**


(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306302-69-2 USPATFULL
 CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny1)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:3)
 (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3
 CMF C19 H21 F N2 O4


Absolute stereochemistry. Rotation (-).



CM 2

CRN 74-79-3
 CMF C6 H14 N4 O2
 CDES 5:L

Absolute stereochemistry.




IT 306302-67-0P
 (antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)
 RN 306302-67-0 USPATFULL
 CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny1)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:1)
 (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3
 CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



L62 ANSWER 7 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2003:208156 USPATFULL
 TITLE: Chiral fluoroquinolone arginine salt forms
 INVENTOR(S): De Souza, Noel J., Chikaltana, INDIA
 Agarwal, Shivkumar, Chikaltana, INDIA
 Patel, Mahesh V., Chikaltana, INDIA
 Bhawsar, Satish B., Chikaltana, INDIA
 Beri, Rupinder K., Chikaltana, INDIA
 Yeole, Ravindra D., Chikaltana, INDIA
 Shetty, Nitin, Chikaltana, INDIA
 PATENT ASSIGNEE(S): WOCHKHARDT LIMITED (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003144517	A1	20030731	<--
	US 6753333	B2	20040622	
APPLICATION INFO.:	US 2002-303692	A1	20021122	(10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-802793, filed on 9 Mar 2001, GRANTED, Pat. No. US 6514986 Continuation of Ser. No. US 2000-640947, filed on 17 Aug 2000, PENDING			
	Continuation-in-part of Ser. No. US 2000-566875, filed on 8 May 2000, PENDING			

	NUMBER	DATE	
PRIORITY INFORMATION:	WO 2000-IN111	20001121	<--
	US 1999-170676P	19991214 (60)	<--

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: LADAS & PARRY, 26 WEST 61ST STREET, NEW YORK, NY, 10023
 NUMBER OF CLAIMS: 55
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 6 Drawing Page(s)
 LINE COUNT: 844

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the new arginine salt forms of
 S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-
 1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their
 preparation and pharmaceutical formulations which comprise those
 arginine salt forms as the active ingredient for its use in treating
 antimicrobial infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 306748-89-0P

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306748-89-0 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-
 methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX
 NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



IT 306302-69-2P

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306302-69-2 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate], hydrate (4:3)
(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



IT 306302-67-0P

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306302-67-0 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate], hydrate (4:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



L62 ANSWER 8 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2003:140970 USPATFULL

TITLE: Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-Quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments

INVENTOR(S): De Souza, Noel John, Mumbai, INDIA
 Patel, Mahesh Vithalbhai, Aurangabad, INDIA
 Deshpande, Prasad Keshav, Aurangabad, INDIA
 Agarwal, Shiv Kumar, Aurangabad, INDIA
 Gupte, Shrikant V., Aurangabad, INDIA
 Upadhyay, Dilip J., Mumbai, INDIA
 Bhawsar, Satish B., Aurangabad, INDIA
 Beri, Rupinder K., Aurangabad, INDIA
 Sreenivas, Kandepu, Aurangabad, INDIA
 Nair, Sheela Chandrasekharan, Aurangabad, INDIA
 Shukla, Milind Chintaman, Aurangabad, INDIA
 Chugh, Yati, Aurangabad, INDIA
 Shetty, Nitin, Aurangabad, INDIA
 Yeole, Ravindra D., Aurangabad, INDIA
 Reddy, M. Madhav, Aurangabad, INDIA

PATENT ASSIGNEE(S): WOCKHARDT LIMITED (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003096812	A1	20030522	<--
APPLICATION INFO.:	US 2002-128996	A1	20020423	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-286291P	20010425 (60)	<--
	US 2001-287104P	20010427 (60)	<--
	US 2001-341165P	20011213 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LADAS & PARRY, 26 WEST 61ST STREET, NEW YORK, NY, 10023		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6020		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to new generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, to their optical isomers, diastereomers or enantiomers, as well as pharmaceutically acceptable salts, hydrates, prodrugs, polymorphs and pseudopolymorphs thereof, to their preparation, to their compositions and to their use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **306748-89-0P**

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306748-89-0 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



IT 306302-69-2P

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306302-69-2 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:3)
(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



IT 306302-67-0P

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306302-67-0 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



L62 ANSWER 9 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2002:315076 USPATFULL

TITLE: Inhibitors of cellular efflux pumps of microbes

INVENTOR(S): de Souza, Noel John, Mumbai, INDIA

Patel, Mahesh Vithalbhai, Aurangabad, INDIA

Gupte, Shrikant V., Aurangabad, INDIA

Upadhyay, Dilip J., Mumbai, INDIA

Shukla, Milind Chintaman, Aurangabad, INDIA

Chaturvedi, Nishith C., Aurangabad, INDIA

Bhawsar, Satish B., Aurangabad, INDIA

Nair, Sheela Chandresekharan, Aurangabad, INDIA

Jafri, Mohammed A., Uttar Pradesh, INDIA

Khorakiwala, Habil Fakhruddin, Mumbai, INDIA

PATENT ASSIGNEE(S): WOCKHARDT LIMITED (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002177559	A1	20021128	<--
APPLICATION INFO.:	US 2001-919347	A1	20010731	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-222201P	20000801 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LADAS & PARRY, 26 WEST 61ST STREET, NEW YORK, NY, 10023		
NUMBER OF CLAIMS:	58		
EXEMPLARY CLAIM:	1		
LINE COUNT:	5750		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds are described which are efflux pump inhibitors of cellular efflux pumps of microbes. Also described are methods of preparing such compounds, methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 306748-89-0P

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306748-89-0 USPTAFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



IT 306302-69-2P

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306302-69-2 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:3)
(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



IT 306302-67-0P

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306302-67-0 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



L62 ANSWER 10 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2002:295181 USPATFULL

TITLE: Antibacterial chiral 8-(substituted piperidino)-benzo
[i,j] quinolizines, processes, compositions and methods
of treatmentINVENTOR(S): De Souza, Noel John, Mumbai, INDIA
Patel, Mahesh Vithalbhair, Aurangabad, INDIA
Agarwal, Shiv Kumar, Sector, INDIA
Gupte, Shirkant V., Cidco Aurangabad, INDIA
Upadhyay, Dilip J., Mumbai, INDIA
Bhawsar, Satish B., Kotwalpura Mil Corner Aurangabad,
INDIAPATENT ASSIGNEE(S): Jafri, Mohammad A., Uttar Pradesh, INDIA
WOCKHARDT RESEARCH CENTER (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002165227	A1	20021107	<--
	US 6608078	B2	20030819	
APPLICATION INFO.:	US 2001-850669	A1	20010507	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-202459P	20000508	(60) <--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	William R. Evans, c/o Ladas & Parry, 26 West 61st Street, New York, NY, 10023		

NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 2969

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to optically pure 8-(substituted piperidino)-benzo[i,j]quinolizines, their isomers, derivatives, salts, pseudopolymorphs, polymorphs prodrugs and hydrates thereof, to processes for their preparation, and to pharmaceutical compositions comprising 8-(substituted piperidino)-benzo[i,j]quinolizines their isomers, derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof. These compounds and compositions possess potent activity in treating local and systemic infections, particularly infections caused by sensitive and resistant Gram-positive organism infections, Gram-negative organism infections, mycobacterial infections and nosocomial pathogens, and particularly those belonging to the staphylococcus, streptococcus and enterococcus groups. Methods for treating the diseases and disorders arising from the foregoing infections in humans and animals are described by administering the compounds of the invention to said humans and animals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 306748-89-0P

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306748-89-0 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



IT 306302-69-2P

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306302-69-2 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate], hydrate (4:3)
(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



IT 306302-67-0P

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306302-67-0 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate], hydrate (4:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



L62 ANSWER 11 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2002:119920 USPATFULL

TITLE: Chiral fluoroquinolone arginine salt forms

INVENTOR(S): de Souza, Noel J., Chikaltana, INDIA

Agarwal, Shivkumar, Chikaltana, INDIA

Patel, Mahesh V., Chikaltana, INDIA

Bhawsar, Satish B., Chikaltana, INDIA

Beri, Rupinder K., Chikaltana, INDIA

Yeole, Ravindra D., Chikaltana, INDIA

Shetty, Nitin, Chikaltana, INDIA

Khorakiwala, Habil F., Mumbai, INDIA

PATENT ASSIGNEE(S): WOCHKHARDT LTD (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002061908	A1	20020523	
	US 6514986	B2	20030204	<--
APPLICATION INFO.:	US 2001-802793	A1	20010309	(9)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: WO 2000-IN111 20001121 <--
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Ladas & Parry, 26 West 61 Street, New York, NY, 10023
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 845

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the new arginine salt forms of
S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-
1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their
preparation and pharmaceutical formulations which comprise those
arginine salt forms as the active ingredient for its use in treating
antimicrobial infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 306748-89-0P

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306748-89-0 USPTFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-
methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate] (9CI) (CA INDEX
NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.

**IT 306302-69-2P**

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306302-69-2 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate], hydrate (4:3)
(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.

**IT 306302-67-0P**

(antibacterial optically pure benzoquinolizinecarboxylic acid derivs.)

RN 306302-67-0 USPATFULL


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate], hydrate (4:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

CDES 5:L

Absolute stereochemistry.



=> d ibib abs ind hitstr 149 1-3

149 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1065524 HCAPLUS

DOCUMENT NUMBER: 142:48568

TITLE: Antistaphylococcal activity of WCK 771, a tricyclic **fluoroquinolone**, in animal infection models

AUTHOR(S): Patel, Mahesh V.; De Souza, Noel J.

; Gupta, Shrikant V.; Jafri, Mohammad A.;

Bhagwat, Sachin S.; Chugh, Yati; Khorakiwala, Habil

F.; Jacobs, Michael R.; Appelbaum, Peter C.

CORPORATE SOURCE: Wockhardt Research Center, Aurangabad, India

SOURCE: Antimicrobial Agents and Chemotherapy (2004), 48(12), 4754-4761

CODEN: AMACQ; ISSN: 0066-4804

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB WCK 771, the **arginine** salt of S-(-)-nadifloxacin, was evaluated in animal models of staphylococcal infection and in vitro. For 302 methicillin-susceptible strains the MIC at which 50% of isolates are inhibited (MIC50) and the MIC90 of WCK 771 were 0.03 and 0.03 µg/mL, resp., and for 198 methicillin-resistant strains the MIC50 and the MIC90 were 0.5 and 1.0 µg/mL, resp. All methicillin-susceptible staphylococci were quinolone susceptible, and almost all methicillin-resistant staphylococci were quinolone resistant. WCK 771 was more potent than moxifloxacin, trovafloxacin, levofloxacin, and ciprofloxacin and had potency comparable to that of clinafloxacin. Only WCK 771 and clinafloxacin demonstrated strong potencies against vancomycin-intermediate Staphylococcus aureus strains (MICs = 1 µg/mL). WCK 771 is not a substrate of the NorA pump, as evident from the lack of an effect of reserpine on the MICs and similar protective doses against infections caused by efflux-pos. and -neg. staphylococci. WCK 771 was effective by both the oral and the s.c. routes in mice infected i.p. with quinolone-susceptible methicillin-susceptible S. aureus (MSSA) strains. For infections caused by quinolone-resistant methicillin-resistant S. aureus (MRSA) strains, the activity of WCK 771 administered s.c. was superior to those of trovafloxacin and sparfloxacin, with a 50% ED range of 27.8 to 46.8 mg/kg of body weight. The activity of WCK 771 was superior to those of moxifloxacin, vancomycin, and linezolid in a mouse cellulitis model of infection caused by one MSSA and two MRSA strains, with EDs of 2.5 and 5 mg/kg for the MSSA strain and 10-fold higher EDs for MRSA strains. WCK 771, like vancomycin and linezolid, eradicated MRSA from mouse liver, spleen, kidney, and lung when it was administered s.c. at a dose of 50 mg/kg for four doses. These studies have demonstrated the effectiveness of WCK 771, administered orally and parenterally, for the treatment of diverse staphylococcal infections in mice, including those caused by quinolone-resistant strains.

CC 1-5 (Pharmacology)

Section cross-reference(s): 10

ST tricyclic **fluoroquinolone** WCK 771 antibacterial Staphylococcus

IT Staphylococcus aureus

(antistaphylococcal activity of WCK 771, a tricyclic **fluoroquinolone**, in animal infection models)

IT 85721-33-1, Ciprofloxacin 100986-85-4, Levofloxacin 105956-97-6, Clinafloxacin 110871-86-8, Sparfloxacin 147059-72-1, Trovafloxacin 151096-09-2, Moxifloxacin 165800-03-3, Linezolid **306748-89-0**, WCK 771

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(antistaphylococcal activity of WCK 771, a tricyclic **fluoroquinolone**, in animal infection models)

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antistaphylococcal activity of WCK 771, a tricyclic **fluoroquinolone**, in animal infection models)


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L49 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:951022 HCAPLUS

DOCUMENT NUMBER: 140:8837

TITLE: Preparation of crystalline **fluoroquinolone arginine** salt form

INVENTOR(S) : De Souza, Noel J.; Deshpande, Prasad
K.; Shukla, Milind C.; Mukarram,

Siddiqui M. Jaweed; Kulkarni, Dilip G.;
Yeole, Ravindra D.; Patel, Mahesh V.;
Gupte, Shrikant V.
 PATENT ASSIGNEE(S): Wockhardt Limited, India
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099815	A1	20031204	WO 2002-IN123	20020528
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2459407	AA	20031204	CA 2002-2459407	20020528
EP 1509519	A1	20050302	EP 2002-743615	20020528
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005527629	T2	20050915	JP 2004-507472	20020528
PRIORITY APPLN. INFO.:			WO 2002-IN123	W 20020528
AB	The invention relates to the new arginine salt forms of RS-(+)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo- 1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, S-(-)-9-fluoro-6,7-dihydro- 8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2- carboxylic acid, R-(+)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5- methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their preparation and pharmaceutical formulations which comprise those arginine salt forms as the active ingredient for its use in treating microbial infections. Thus, S-(-)-9-fluoro-6,7-dihydro-8-(4- hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2- carboxylic acid (I) was treated with L- arginine in acetone solution to give the I arginine salt.			
IC	ICM C07D455-04 ICS A61K031-4375; A61P031-04			
CC	63-6 (Pharmaceuticals) Section cross-reference(s): 28			
ST	fluoroquinolone arginine salt cryst prepn			
IT	Microorganism (infection with; preparation of crystalline fluoroquinolone arginine salts)			
IT	Crystal structure (of fluoroquinolone arginine salts)			
IT	Crystallinity Density Drug delivery systems (preparation of crystalline fluoroquinolone arginine salts)			
IT	64-17-5, Ethanol, uses 67-56-1, Methanol, uses 67-63-0, 2-Propanol, uses 67-64-1, Acetone, uses 75-05-8, Acetonitrile, uses			

RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process); USES (Uses)
 (preparation of crystalline **fluoroquinolone arginine salts**)

IT 306748-89-0P 627891-29-6P 627891-34-3P
 628705-85-1P 628705-87-3P 628705-88-4P
 628705-89-5P 628705-90-8P 628705-91-9P
 628705-94-2P 628705-96-4P 628705-98-6P
 628706-00-3P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of crystalline **fluoroquinolone arginine salts**)

IT 74-79-3, L-Arginine, reactions 157-06-2, D-Arginine

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of crystalline **fluoroquinolone arginine salts**)


IT 124858-35-1 154357-42-3 160961-35-3

RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (preparation of crystalline **fluoroquinolone arginine salts**)


IT 64-17-5, Ethanol, uses 67-56-1, Methanol, uses 67-63-0, 2-Propanol, uses 67-64-1, Acetone, uses 75-05-8, Acetonitrile, uses

RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process); USES (Uses)
 (preparation of crystalline **fluoroquinolone arginine salts**)


RN 64-17-5 HCAPLUS
 CN Ethanol (9CI) (CA INDEX NAME)




RN 67-56-1 HCAPLUS
 CN Methanol (8CI, 9CI) (CA INDEX NAME)




RN 67-63-0 HCAPLUS
 CN 2-Propanol (9CI) (CA INDEX NAME)



RN 67-64-1 HCAPLUS
 CN 2-Propanone (9CI) (CA INDEX NAME)



RN 75-05-8 HCAPLUS
 CN Acetonitrile (8CI, 9CI) (CA INDEX NAME)



IT 306748-89-0P 627891-29-6P 627891-34-3P
 628705-85-1P 628705-87-3P 628705-88-4P
 628705-89-5P 628705-90-8P 628705-91-9P
 628705-94-2P 628705-96-4P 628705-98-6P
 628706-00-3P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of crystalline **fluoroquinolone arginine salts**)

RN 306748-89-0 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 627891-29-6 HCAPLUS


CN L-Arginine, (5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate (3:2) (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 627891-34-3 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], monohydrate (9CI)
(CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 628705-85-1 HCAPLUS


CN L-Arginine, (5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate, hydrate (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 628705-87-3 HCAPLUS


CN L-Arginine, (5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 628705-88-4 HCAPLUS


CN D-Arginine, (5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 157-06-2

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 628705-89-5 HCAPLUS


CN L-Arginine, (5R)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 160961-35-3

CMF C19 H21 F N2 O4


Absolute stereochemistry. Rotation (+).



CM 2

CRN 74-79-3
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 628705-90-8 HCAPLUS
CN D-Arginine, (5R)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny1)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 160961-35-3
CMF C19 H21 F N2 O4


Absolute stereochemistry. Rotation (+).



CM 2

CRN 157-06-2
CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 628705-91-9 HCAPLUS
CN L-Arginine, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny1)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate (9CI) (CA INDEX NAME)

CM 1


CRN 124858-35-1
CMF C19 H21 F N2 O4



CM 2

CRN 74-79-3
CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 628705-94-2 HCAPLUS
CN D-Arginine, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate (9CI) (CA INDEX NAME)

CM 1


CRN 124858-35-1
CMF C19 H21 F N2 O4



CM 2

CRN 157-06-2
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 628705-96-4 HCAPLUS
CN Arginine, (5R)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate (9CI) (CA INDEX NAME)

CM 1


CRN 160961-35-3
CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (+).



CM 2


CRN 7200-25-1
CMF C6 H14 N4 O2



RN 628705-98-6 HCAPLUS
CN Arginine, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate (9CI) (CA INDEX NAME)

CM 1


CRN 124858-35-1
CMF C19 H21 F N2 O4



CM 2

CRN 7200-25-1

CMF C6 H14 N4 O2



RN 628706-00-3 HCAPLUS


CN Arginine, (5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4


Absolute stereochemistry. Rotation (-).



CM 2

CRN 7200-25-1

CMF C6 H14 N4 O2



IT 74-79-3, L-Arginine, reactions 157-06-2, D-

Arginine


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of crystalline **fluoroquinolone arginine salts**)

RN 74-79-3 HCAPLUS

CN L-Arginine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157-06-2 HCAPLUS

CN D-Arginine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 124858-35-1 154357-42-3 160961-35-3

RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)

(preparation of crystalline **fluoroquinolone arginine salts**)

RN 124858-35-1 HCAPLUS


CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny)-5-methyl-1-oxo- (9CI) (CA INDEX NAME)



RN 154357-42-3 HCAPLUS

CN 1H,5H-Benzo[*ij*]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 160961-35-3 HCAPLUS

CN 1H,5H-Benzo[*ij*]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L49 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:950059 HCAPLUS

DOCUMENT NUMBER: 140:8806

TITLE: Preparation of crystalline **fluoroquinolone arginine** salts for pharmaceuticals

INVENTOR(S): **De Souza, Noel J.; Deshpande, Prasad K.; Shukla, Milind C.; Jaweed, Mukarram Siddiqui M.; Kulkarni, Dilip Ganesh; Rahman, Ansari Azizur; Yeole, Ravindra D.; Patel, Mahesh V.; Gupte, Shrikant V.**

PATENT ASSIGNEE(S): Wockhardt Limited, India

SOURCE: U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003225119	A1	20031204	US 2002-156685	20020528
US 6664267	B2	20031216		
US 2004063948	A1	20040401	US 2003-671040	20030925
PRIORITY APPLN. INFO.:			US 2002-156685	A3 20020528

AB The invention relates to the new **arginine** salt forms of RS-(±)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid (I), R-(+)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their preparation and pharmaceutical formulations which comprise those **arginine** salt forms as the active ingredient for its use in treating microbial infections. I was suspended in acetone, and this suspension was mixed with L-**arginine** and water. The mixture was stirred at 55-60° to obtain a clear solution and to this solution was added activated carbon and the solution was filtered. To the filtrate was added acetone, and the reaction mixture was stirred for an addnl. for 2 h at 30-35°, and then allowed to cool to 5°. The obtained solid was filtered and washed with acetone. The wet solid was dried at 80-85° to afford the L L-**arginine** salt hydrate. as a cream colored powder.

IC ICM C07D471-04
ICS A61K031-4745

INCL 514296000; 546098000

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 27

ST cryst **fluoroquinolone arginine** salt pharmaceutical prepn

IT Eubacteria
(infection with; preparation of crystalline **fluoroquinolone arginine** salts for pharmaceuticals)


IT Antibacterial agents
Drug delivery systems
(preparation of crystalline **fluoroquinolone arginine** salts for pharmaceuticals)

IT 64-17-5, Ethanol, processes 67-56-1, Methanol, processes 67-63-0, 2-Propanol, processes 67-64-1, Acetone, processes 75-05-8, Acetonitrile, processes
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)
(preparation of crystalline **fluoroquinolone arginine** salts for pharmaceuticals)


IT 306302-67-0P 306302-69-2P 306748-89-0P
371246-52-5P 396132-50-6P 627891-14-9P
627891-18-3P 627891-20-7P 627891-23-0P
627891-25-2P 627891-29-6P 627891-31-0P
627891-34-3P 627891-36-5P 627891-38-7P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystalline **fluoroquinolone arginine** salts for pharmaceuticals)

IT 74-79-3, L-**Arginine**, reactions 157-06-2, D-**Arginine** 7200-25-1, **Arginine** 124858-35-1 154357-42-3 160961-35-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of crystalline **fluoroquinolone arginine** salts for pharmaceuticals)


IT 64-17-5, Ethanol, processes 67-56-1, Methanol, processes
 67-63-0, 2-Propanol, processes 67-64-1, Acetone,
 processes 75-05-8, Acetonitrile, processes
 RL: PEP (Physical, engineering or chemical process); PYP (Physical
 process); PROC (Process)
 (preparation of crystalline **fluoroquinolone arginine salts**
 for pharmaceuticals)
 RN 64-17-5 HCAPLUS
 CN Ethanol (9CI) (CA INDEX NAME)




RN 67-56-1 HCAPLUS
 CN Methanol (8CI, 9CI) (CA INDEX NAME)




RN 67-63-0 HCAPLUS
 CN 2-Propanol (9CI) (CA INDEX NAME)



RN 67-64-1 HCAPLUS
 CN 2-Propanone (9CI) (CA INDEX NAME)



RN 75-05-8 HCAPLUS
 CN Acetonitrile (8CI, 9CI) (CA INDEX NAME)




IT 306302-67-0P 306302-69-2P 306748-89-0P
 371246-52-5P 396132-50-6P 627891-14-9P
 627891-18-3P 627891-20-7P 627891-23-0P
 627891-25-2P 627891-29-6P 627891-31-0P
 627891-34-3P 627891-36-5P 627891-38-7P
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of crystalline **fluoroquinolone arginine salts**
 for pharmaceuticals)
 RN 306302-67-0 HCAPLUS
 CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-
 methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:1)
 (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 306302-69-2 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (4:3)
(9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 306748-89-0 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 371246-52-5 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], hydrate (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 396132-50-6 HCAPLUS

CN L-Arginine, mono[(R)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 160961-35-3
CMF C19 H21 F N2 O4


Absolute stereochemistry. Rotation (+).



CM 2

CRN 74-79-3
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 627891-14-9 HCAPLUS
CN D-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3
CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 157-06-2

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 627891-18-3 HCAPLUS


CN D-Arginine, mono[(5R)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 160961-35-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (+).




CM 2

CRN 157-06-2

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 627891-20-7 HCAPLUS

CN L-Arginine, mono[9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 124858-35-1

CMF C19 H21 F N2 O4




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 627891-23-0 HCAPLUS

CN Arginine, mono[9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 124858-35-1


CMF C19 H21 F N2 O4



CM 2

CRN 7200-25-1

CMF C6 H14 N4 O2



RN 627891-25-2 HCAPLUS


CN Arginine, mono[(5R)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 160961-35-3

CMF C19 H21 F N2 O4


Absolute stereochemistry. Rotation (+).



CM 2

CRN 7200-25-1

CMF C6 H14 N4 O2



RN 627891-29-6 HCAPLUS


CN L-Arginine, (5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate (3:2) (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 627891-31-0 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-2-carboxylate], hydrate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 627891-34-3 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], monohydrate (9CI)
(CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 627891-36-5 HCAPLUS


CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], dihydrate (9CI)
(CA INDEX NAME)

CM 1

CRN 154357-42-3

CMF C19 H21 F N2 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 627891-38-7 HCAPLUS

CN L-Arginine, mono[(5S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylate], trihydrate (9CI)
(CA INDEX NAME)

CM 1

CRN 154357-42-3
CMF C19 H21 F N2 O4


Absolute stereochemistry. Rotation (-).



CM 2


CRN 74-79-3
CMF C6 H14 N4 O2

Absolute stereochemistry.




IT 74-79-3, L-Arginine, reactions 157-06-2, D-Arginine 7200-25-1, Arginine 124858-35-1 154357-42-3 160961-35-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of crystalline fluoroquinolone arginine salts for pharmaceuticals)
RN 74-79-3 HCAPLUS
CN L-Arginine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 157-06-2 HCAPLUS
CN D-Arginine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 7200-25-1 HCAPLUS
CN Arginine (9CI) (CA INDEX NAME)




RN 124858-35-1 HCAPLUS
CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny)-5-methyl-1-oxo- (9CI) (CA INDEX NAME)



RN 154357-42-3 HCAPLUS
CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny)-5-methyl-1-oxo-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 160961-35-3 HCAPLUS
CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidiny)-5-methyl-1-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

